- Home
- PLRX vs AUTL Comparison
PLRX vs AUTL Comparison
Compare PLRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | AUTL |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9M | 431.2M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PLRX | AUTL |
|---|---|---|
| Price | $1.25 | $1.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.67 | ★ $8.50 |
| AVG Volume (30 Days) | 458.6K | ★ 1.4M |
| Earning Date | 03-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | 28.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $669.62 |
| Revenue Next Year | N/A | $79.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $1.09 | $1.11 |
| 52 Week High | $1.95 | $2.70 |
Technical Indicators
Market Signals| Indicator | PLRX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 35.39 |
| Support Level | $1.12 | $1.23 |
| Resistance Level | $1.36 | $1.52 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 2.56 | 2.56 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.